- Home
- SYBX vs PVLA Comparison
SYBX vs PVLA Comparison
Compare SYBX & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- PVLA
- Stock Information
- Founded
- SYBX N/A
- PVLA 2015
- Country
- SYBX United States
- PVLA United States
- Employees
- SYBX N/A
- PVLA N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- PVLA Health Care
- Exchange
- SYBX Nasdaq
- PVLA Nasdaq
- Market Cap
- SYBX 16.5M
- PVLA 15.9M
- IPO Year
- SYBX N/A
- PVLA N/A
- Fundamental
- Price
- SYBX $1.43
- PVLA $13.15
- Analyst Decision
- SYBX Hold
- PVLA Strong Buy
- Analyst Count
- SYBX 3
- PVLA 1
- Target Price
- SYBX $1.00
- PVLA $38.00
- AVG Volume (30 Days)
- SYBX 24.4K
- PVLA 39.6K
- Earning Date
- SYBX 03-18-2025
- PVLA 02-15-2025
- Dividend Yield
- SYBX N/A
- PVLA N/A
- EPS Growth
- SYBX N/A
- PVLA N/A
- EPS
- SYBX N/A
- PVLA N/A
- Revenue
- SYBX $2,777,000.00
- PVLA N/A
- Revenue This Year
- SYBX N/A
- PVLA N/A
- Revenue Next Year
- SYBX N/A
- PVLA N/A
- P/E Ratio
- SYBX N/A
- PVLA N/A
- Revenue Growth
- SYBX 292.23
- PVLA N/A
- 52 Week Low
- SYBX $1.22
- PVLA $6.20
- 52 Week High
- SYBX $3.73
- PVLA $22.32
- Technical
- Relative Strength Index (RSI)
- SYBX 49.27
- PVLA N/A
- Support Level
- SYBX $1.36
- PVLA N/A
- Resistance Level
- SYBX $1.47
- PVLA N/A
- Average True Range (ATR)
- SYBX 0.08
- PVLA 0.00
- MACD
- SYBX 0.00
- PVLA 0.00
- Stochastic Oscillator
- SYBX 43.75
- PVLA 0.00
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.